Caribou Biosciences (CRBU) announced the FDA granted Fast Track designations to CB-010 for refractory systemic lupus erythematosus and to CB-012 for relapsed or refractory acute myeloid leukemia. CB-010 will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis and extrarenal lupus, subcategories of SLE. The GALLOP clinical trial is on track to initiate by year-end 2024.
CB-012 is being evaluated in the ongoing AMpLify Phase 1 clinical trial in patients with r/r AML.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.